A phase I pharmacokinetic study of the vascular disrupting agent ombrabulin (AVE8062) and docetaxel in advanced solid tumours View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2014-04

AUTHORS

F A L M Eskens, P Tresca, D Tosi, L Van Doorn, H Fontaine, A Van der Gaast, C Veyrat-Follet, C Oprea, M Hospitel, V Dieras

ABSTRACT

BACKGROUND: The vascular disrupting agent ombrabulin shows synergy with docetaxel in vivo. Recommended phase II doses were determined in a dose escalation study in advanced solid tumours. METHODS: Ombrabulin (30-min infusion, day 1) followed by docetaxel (1-h infusion, day 2) every 3 weeks was explored. Ombrabulin was escalated from 11.5 to 42 mg m(-2) with 75 mg m(-2) docetaxel, then from 30 to 35 mg m(-2) with 100 mg m(-2) docetaxel. Recommended phase II dose cohorts were expanded. RESULTS: Fifty-eight patients were treated. Recommended phase II doses were 35 mg m(-2) ombrabulin with 75 mg m(-2) docetaxel (35/75 mg m(-2); 13 patients) and 30 mg m(-2) ombrabulin with 100 mg m(-2) docetaxel (30/100 mg m(-2); 16 patients). Dose-limiting toxicities were grade 3 fatigue (two patients; 42/75, 35/100), grade 3 neutropaenic infection (25/75), grade 3 headache (42/75), grade 4 febrile neutropaenia (30/100), and grade 3 thrombosis (35/100). Toxicities were consistent with each agent; mild nausea/vomiting, asthaenia/fatigue, alopecia, and anaemia were common, as were neutropaenia and leukopaenia. Diarrhoea, nail disorders and neurological symptoms were frequent at 100 mg m(-2) docetaxel. Pharmacokinetic analyses did not show any relevant drug interactions. Ten patients had partial responses (seven at 30 mg m(-2) ombrabulin), eight lasting >3 months. CONCLUSIONS: Sequential administration of ombrabulin with 75 or 100 mg m(-2) docetaxel every 3 weeks is feasible. More... »

PAGES

2170

Identifiers

URI

http://scigraph.springernature.com/pub.10.1038/bjc.2014.137

DOI

http://dx.doi.org/10.1038/bjc.2014.137

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1000864041

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/24714750


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adolescent", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Angiogenesis Inhibitors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Combined Chemotherapy Protocols", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Interactions", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Serine", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Taxoids", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Young Adult", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Erasmus University Medical Center", 
          "id": "https://www.grid.ac/institutes/grid.5645.2", 
          "name": [
            "Department of Medical Oncology, Erasmus MC Cancer Institute, PO Box 2040, 3000 CA Rotterdam, The Netherlands."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Eskens", 
        "givenName": "F A L M", 
        "id": "sg:person.07565335014.02", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07565335014.02"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Institute Curie", 
          "id": "https://www.grid.ac/institutes/grid.418596.7", 
          "name": [
            "Clinical Research Unit, Institut Curie, 26, rue d'Ulm, 75231 Paris Cedex 05, France."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Tresca", 
        "givenName": "P", 
        "id": "sg:person.0676412775.30", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0676412775.30"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Institute Curie", 
          "id": "https://www.grid.ac/institutes/grid.418596.7", 
          "name": [
            "Clinical Research Unit, Institut Curie, 26, rue d'Ulm, 75231 Paris Cedex 05, France."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Tosi", 
        "givenName": "D", 
        "id": "sg:person.0712330270.51", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0712330270.51"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Erasmus University Medical Center", 
          "id": "https://www.grid.ac/institutes/grid.5645.2", 
          "name": [
            "Department of Medical Oncology, Erasmus MC Cancer Institute, PO Box 2040, 3000 CA Rotterdam, The Netherlands."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Van Doorn", 
        "givenName": "L", 
        "id": "sg:person.01322677514.61", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01322677514.61"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Sanofi (France)", 
          "id": "https://www.grid.ac/institutes/grid.417924.d", 
          "name": [
            "Oncology Division and Trial Operations Department, Sanofi, 13 Quai Jules Guesde, 94400 Vitry-Sur-Seine, France."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Fontaine", 
        "givenName": "H", 
        "id": "sg:person.01026556670.47", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01026556670.47"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Erasmus University Medical Center", 
          "id": "https://www.grid.ac/institutes/grid.5645.2", 
          "name": [
            "Department of Medical Oncology, Erasmus MC Cancer Institute, PO Box 2040, 3000 CA Rotterdam, The Netherlands."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Van der Gaast", 
        "givenName": "A", 
        "id": "sg:person.01151436636.46", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01151436636.46"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Sanofi (France)", 
          "id": "https://www.grid.ac/institutes/grid.417924.d", 
          "name": [
            "Division of Drug Disposition DSAR, Sanofi, 1 Avenue Pierre Brossolette, 91380 Chilly-Mazarin, France."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Veyrat-Follet", 
        "givenName": "C", 
        "id": "sg:person.01105742745.38", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01105742745.38"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Sanofi (France)", 
          "id": "https://www.grid.ac/institutes/grid.417924.d", 
          "name": [
            "Oncology Division and Trial Operations Department, Sanofi, 13 Quai Jules Guesde, 94400 Vitry-Sur-Seine, France."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Oprea", 
        "givenName": "C", 
        "id": "sg:person.01313363470.43", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01313363470.43"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Sanofi (France)", 
          "id": "https://www.grid.ac/institutes/grid.417924.d", 
          "name": [
            "Division of Biostatistics & Programming, Sanofi, 13 Quai Jules Guesde, 94400 Vitry-Sur-Seine, France."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hospitel", 
        "givenName": "M", 
        "id": "sg:person.01276413771.32", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01276413771.32"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Institute Curie", 
          "id": "https://www.grid.ac/institutes/grid.418596.7", 
          "name": [
            "Clinical Research Unit, Institut Curie, 26, rue d'Ulm, 75231 Paris Cedex 05, France."
          ], 
          "type": "Organization"
        }, 
        "familyName": "Dieras", 
        "givenName": "V", 
        "id": "sg:person.01104241537.43", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01104241537.43"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s002800050611", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1000213160", 
          "https://doi.org/10.1007/s002800050611"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0959-8049(99)00174-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1000814734"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.bjc.6600645", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1000892697", 
          "https://doi.org/10.1038/sj.bjc.6600645"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.bjc.6600645", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1000892697", 
          "https://doi.org/10.1038/sj.bjc.6600645"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-13-0427", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003465176"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/0008-5472.can-06-4018", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003856751"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00280-002-0529-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1006440096", 
          "https://doi.org/10.1007/s00280-002-0529-0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf02353487", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008091929", 
          "https://doi.org/10.1007/bf02353487"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1182/blood.v99.6.2060", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008985812"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-11-3376", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012763105"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nrc1628", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017276673", 
          "https://doi.org/10.1038/nrc1628"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nrc1628", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017276673", 
          "https://doi.org/10.1038/nrc1628"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nrc1628", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017276673", 
          "https://doi.org/10.1038/nrc1628"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2005.02.027", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017384575"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdr413", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018078452"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.bjc.6601261", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019402280", 
          "https://doi.org/10.1038/sj.bjc.6601261"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.bjc.6601261", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019402280", 
          "https://doi.org/10.1038/sj.bjc.6601261"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2005.05.0294", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026468715"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/cncr.24975", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026739049"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/cncr.24975", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026739049"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/jnci/92.3.205", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032301848"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0959-8049(99)00122-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1039441230"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.1999.17.5.1413", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1074460860"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.1999.17.8.2341", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1074549851"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1082649028", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.1998.16.1.187", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1083201635"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2014-04", 
    "datePublishedReg": "2014-04-01", 
    "description": "BACKGROUND: The vascular disrupting agent ombrabulin shows synergy with docetaxel in vivo. Recommended phase II doses were determined in a dose escalation study in advanced solid tumours.\nMETHODS: Ombrabulin (30-min infusion, day 1) followed by docetaxel (1-h infusion, day 2) every 3 weeks was explored. Ombrabulin was escalated from 11.5 to 42\u2009mg\u2009m(-2) with 75\u2009mg\u2009m(-2) docetaxel, then from 30 to 35\u2009mg\u2009m(-2) with 100\u2009mg\u2009m(-2) docetaxel. Recommended phase II dose cohorts were expanded.\nRESULTS: Fifty-eight patients were treated. Recommended phase II doses were 35\u2009mg\u2009m(-2) ombrabulin with 75\u2009mg\u2009m(-2) docetaxel (35/75\u2009mg\u2009m(-2); 13 patients) and 30\u2009mg\u2009m(-2) ombrabulin with 100\u2009mg\u2009m(-2) docetaxel (30/100\u2009mg\u2009m(-2); 16 patients). Dose-limiting toxicities were grade 3 fatigue (two patients; 42/75, 35/100), grade 3 neutropaenic infection (25/75), grade 3 headache (42/75), grade 4 febrile neutropaenia (30/100), and grade 3 thrombosis (35/100). Toxicities were consistent with each agent; mild nausea/vomiting, asthaenia/fatigue, alopecia, and anaemia were common, as were neutropaenia and leukopaenia. Diarrhoea, nail disorders and neurological symptoms were frequent at 100\u2009mg\u2009m(-2) docetaxel. Pharmacokinetic analyses did not show any relevant drug interactions. Ten patients had partial responses (seven at 30\u2009mg\u2009m(-2) ombrabulin), eight lasting >3 months.\nCONCLUSIONS: Sequential administration of ombrabulin with 75 or 100\u2009mg\u2009m(-2) docetaxel every 3 weeks is feasible.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1038/bjc.2014.137", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1017082", 
        "issn": [
          "0007-0920", 
          "1532-1827"
        ], 
        "name": "British Journal of Cancer", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "9", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "110"
      }
    ], 
    "name": "A phase I pharmacokinetic study of the vascular disrupting agent ombrabulin (AVE8062) and docetaxel in advanced solid tumours", 
    "pagination": "2170", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "041dbd756816901ce2fcb29c80a52cdb60c989f848a8dd20bc8571425f331297"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "24714750"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "0370635"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1038/bjc.2014.137"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1000864041"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1038/bjc.2014.137", 
      "https://app.dimensions.ai/details/publication/pub.1000864041"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-10T20:35", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8684_00000435.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://www.nature.com/articles/bjc2014137"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/bjc.2014.137'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/bjc.2014.137'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/bjc.2014.137'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/bjc.2014.137'


 

This table displays all metadata directly associated to this object as RDF triples.

268 TRIPLES      21 PREDICATES      65 URIs      36 LITERALS      24 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1038/bjc.2014.137 schema:about N20d94a7b8fba42e7995f05ad0f85847e
2 N26169ef2ed5347a1b6f974621599bedc
3 N2f60492092da411d9293c244d238975f
4 N57db75b1c8214eb789a0c9ded1b43906
5 N66c8f55be3b142e8a63856292fdf3ad1
6 N703c5ffa1fe945a5a3b7b8a353b404d2
7 N756ac3c45b684467afe507b3b885d272
8 N7cb20e96925e41798ff1a04406f05742
9 N80760b35ca494853a879b4f29f1e760f
10 N87aae2fd20384512ba68e739e027b973
11 Na1003e39d9c045f08da605a61ea11d29
12 Nc0026e82ab0546e684b5183fec99af1f
13 Nc1f53e3d758b4faab5d1439c5c14de81
14 Nec6c2f11c1ba4d8c99205de3b7f46ec9
15 Nf4f7207a31824ea585bf75aa8b9c2cdd
16 anzsrc-for:11
17 anzsrc-for:1103
18 schema:author Nc94638d21a8c4f5d8dbb9bb926ffe5b3
19 schema:citation sg:pub.10.1007/bf02353487
20 sg:pub.10.1007/s00280-002-0529-0
21 sg:pub.10.1007/s002800050611
22 sg:pub.10.1038/nrc1628
23 sg:pub.10.1038/sj.bjc.6600645
24 sg:pub.10.1038/sj.bjc.6601261
25 https://app.dimensions.ai/details/publication/pub.1082649028
26 https://doi.org/10.1002/cncr.24975
27 https://doi.org/10.1016/s0959-8049(99)00122-7
28 https://doi.org/10.1016/s0959-8049(99)00174-4
29 https://doi.org/10.1093/annonc/mdr413
30 https://doi.org/10.1093/jnci/92.3.205
31 https://doi.org/10.1158/0008-5472.can-06-4018
32 https://doi.org/10.1158/1078-0432.ccr-11-3376
33 https://doi.org/10.1158/1078-0432.ccr-13-0427
34 https://doi.org/10.1182/blood.v99.6.2060
35 https://doi.org/10.1200/jco.1998.16.1.187
36 https://doi.org/10.1200/jco.1999.17.5.1413
37 https://doi.org/10.1200/jco.1999.17.8.2341
38 https://doi.org/10.1200/jco.2005.02.027
39 https://doi.org/10.1200/jco.2005.05.0294
40 schema:datePublished 2014-04
41 schema:datePublishedReg 2014-04-01
42 schema:description BACKGROUND: The vascular disrupting agent ombrabulin shows synergy with docetaxel in vivo. Recommended phase II doses were determined in a dose escalation study in advanced solid tumours. METHODS: Ombrabulin (30-min infusion, day 1) followed by docetaxel (1-h infusion, day 2) every 3 weeks was explored. Ombrabulin was escalated from 11.5 to 42 mg m(-2) with 75 mg m(-2) docetaxel, then from 30 to 35 mg m(-2) with 100 mg m(-2) docetaxel. Recommended phase II dose cohorts were expanded. RESULTS: Fifty-eight patients were treated. Recommended phase II doses were 35 mg m(-2) ombrabulin with 75 mg m(-2) docetaxel (35/75 mg m(-2); 13 patients) and 30 mg m(-2) ombrabulin with 100 mg m(-2) docetaxel (30/100 mg m(-2); 16 patients). Dose-limiting toxicities were grade 3 fatigue (two patients; 42/75, 35/100), grade 3 neutropaenic infection (25/75), grade 3 headache (42/75), grade 4 febrile neutropaenia (30/100), and grade 3 thrombosis (35/100). Toxicities were consistent with each agent; mild nausea/vomiting, asthaenia/fatigue, alopecia, and anaemia were common, as were neutropaenia and leukopaenia. Diarrhoea, nail disorders and neurological symptoms were frequent at 100 mg m(-2) docetaxel. Pharmacokinetic analyses did not show any relevant drug interactions. Ten patients had partial responses (seven at 30 mg m(-2) ombrabulin), eight lasting >3 months. CONCLUSIONS: Sequential administration of ombrabulin with 75 or 100 mg m(-2) docetaxel every 3 weeks is feasible.
43 schema:genre research_article
44 schema:inLanguage en
45 schema:isAccessibleForFree true
46 schema:isPartOf N86df970ae6184475bdc5ab13fe08aa91
47 Nd8f7965365a4495db13e393b97bb142f
48 sg:journal.1017082
49 schema:name A phase I pharmacokinetic study of the vascular disrupting agent ombrabulin (AVE8062) and docetaxel in advanced solid tumours
50 schema:pagination 2170
51 schema:productId N1d8f941ea646478daa90b85bb70813cf
52 N36fd0f9cfefd4d978a369519c2379e9d
53 N83801957196c42ada6d1dce0ac9de3d6
54 Nbf48eb6d61624de185bf72d6a52a1c47
55 Ndf27a2986d424b74b1074d5e6523accb
56 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000864041
57 https://doi.org/10.1038/bjc.2014.137
58 schema:sdDatePublished 2019-04-10T20:35
59 schema:sdLicense https://scigraph.springernature.com/explorer/license/
60 schema:sdPublisher Nf7dc34a5b2714263a6e7f33dbf1d31db
61 schema:url https://www.nature.com/articles/bjc2014137
62 sgo:license sg:explorer/license/
63 sgo:sdDataset articles
64 rdf:type schema:ScholarlyArticle
65 N06af07633fa94ca6bfee38b2022e77f9 rdf:first sg:person.01313363470.43
66 rdf:rest N9e60d66471ea40f793d91da376cb74a3
67 N1d8f941ea646478daa90b85bb70813cf schema:name doi
68 schema:value 10.1038/bjc.2014.137
69 rdf:type schema:PropertyValue
70 N1e3f7b6aa2e34e6580ca6b345a3abd6e rdf:first sg:person.01104241537.43
71 rdf:rest rdf:nil
72 N20d94a7b8fba42e7995f05ad0f85847e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
73 schema:name Adolescent
74 rdf:type schema:DefinedTerm
75 N26169ef2ed5347a1b6f974621599bedc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
76 schema:name Adult
77 rdf:type schema:DefinedTerm
78 N2f60492092da411d9293c244d238975f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
79 schema:name Taxoids
80 rdf:type schema:DefinedTerm
81 N36fd0f9cfefd4d978a369519c2379e9d schema:name nlm_unique_id
82 schema:value 0370635
83 rdf:type schema:PropertyValue
84 N57db75b1c8214eb789a0c9ded1b43906 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
85 schema:name Treatment Outcome
86 rdf:type schema:DefinedTerm
87 N66c8f55be3b142e8a63856292fdf3ad1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
88 schema:name Female
89 rdf:type schema:DefinedTerm
90 N6ac83f0428b34bbfb801ec3bfe7a382a rdf:first sg:person.01322677514.61
91 rdf:rest Nd10a0a888ffa48739244170b8f226dc9
92 N703c5ffa1fe945a5a3b7b8a353b404d2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
93 schema:name Male
94 rdf:type schema:DefinedTerm
95 N756ac3c45b684467afe507b3b885d272 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
96 schema:name Middle Aged
97 rdf:type schema:DefinedTerm
98 N793c9dc934194202ab29ae517ed82a06 rdf:first sg:person.0712330270.51
99 rdf:rest N6ac83f0428b34bbfb801ec3bfe7a382a
100 N7cb20e96925e41798ff1a04406f05742 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
101 schema:name Neoplasms
102 rdf:type schema:DefinedTerm
103 N80760b35ca494853a879b4f29f1e760f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
104 schema:name Serine
105 rdf:type schema:DefinedTerm
106 N83801957196c42ada6d1dce0ac9de3d6 schema:name dimensions_id
107 schema:value pub.1000864041
108 rdf:type schema:PropertyValue
109 N86df970ae6184475bdc5ab13fe08aa91 schema:volumeNumber 110
110 rdf:type schema:PublicationVolume
111 N87aae2fd20384512ba68e739e027b973 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
112 schema:name Humans
113 rdf:type schema:DefinedTerm
114 N89865e4bc6ae410db3cfb00d5b9245b2 rdf:first sg:person.01151436636.46
115 rdf:rest Nb60530fdcc424d2aad755ee143df181d
116 N9e60d66471ea40f793d91da376cb74a3 rdf:first sg:person.01276413771.32
117 rdf:rest N1e3f7b6aa2e34e6580ca6b345a3abd6e
118 Na1003e39d9c045f08da605a61ea11d29 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
119 schema:name Angiogenesis Inhibitors
120 rdf:type schema:DefinedTerm
121 Nb60530fdcc424d2aad755ee143df181d rdf:first sg:person.01105742745.38
122 rdf:rest N06af07633fa94ca6bfee38b2022e77f9
123 Nb8fb0c3c7d0444da8b12c04fdcf424a5 rdf:first sg:person.0676412775.30
124 rdf:rest N793c9dc934194202ab29ae517ed82a06
125 Nbf48eb6d61624de185bf72d6a52a1c47 schema:name pubmed_id
126 schema:value 24714750
127 rdf:type schema:PropertyValue
128 Nc0026e82ab0546e684b5183fec99af1f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
129 schema:name Young Adult
130 rdf:type schema:DefinedTerm
131 Nc1f53e3d758b4faab5d1439c5c14de81 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
132 schema:name Drug Interactions
133 rdf:type schema:DefinedTerm
134 Nc94638d21a8c4f5d8dbb9bb926ffe5b3 rdf:first sg:person.07565335014.02
135 rdf:rest Nb8fb0c3c7d0444da8b12c04fdcf424a5
136 Nd10a0a888ffa48739244170b8f226dc9 rdf:first sg:person.01026556670.47
137 rdf:rest N89865e4bc6ae410db3cfb00d5b9245b2
138 Nd8f7965365a4495db13e393b97bb142f schema:issueNumber 9
139 rdf:type schema:PublicationIssue
140 Ndf27a2986d424b74b1074d5e6523accb schema:name readcube_id
141 schema:value 041dbd756816901ce2fcb29c80a52cdb60c989f848a8dd20bc8571425f331297
142 rdf:type schema:PropertyValue
143 Nec6c2f11c1ba4d8c99205de3b7f46ec9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
144 schema:name Antineoplastic Combined Chemotherapy Protocols
145 rdf:type schema:DefinedTerm
146 Nf4f7207a31824ea585bf75aa8b9c2cdd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
147 schema:name Aged
148 rdf:type schema:DefinedTerm
149 Nf7dc34a5b2714263a6e7f33dbf1d31db schema:name Springer Nature - SN SciGraph project
150 rdf:type schema:Organization
151 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
152 schema:name Medical and Health Sciences
153 rdf:type schema:DefinedTerm
154 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
155 schema:name Clinical Sciences
156 rdf:type schema:DefinedTerm
157 sg:journal.1017082 schema:issn 0007-0920
158 1532-1827
159 schema:name British Journal of Cancer
160 rdf:type schema:Periodical
161 sg:person.01026556670.47 schema:affiliation https://www.grid.ac/institutes/grid.417924.d
162 schema:familyName Fontaine
163 schema:givenName H
164 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01026556670.47
165 rdf:type schema:Person
166 sg:person.01104241537.43 schema:affiliation https://www.grid.ac/institutes/grid.418596.7
167 schema:familyName Dieras
168 schema:givenName V
169 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01104241537.43
170 rdf:type schema:Person
171 sg:person.01105742745.38 schema:affiliation https://www.grid.ac/institutes/grid.417924.d
172 schema:familyName Veyrat-Follet
173 schema:givenName C
174 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01105742745.38
175 rdf:type schema:Person
176 sg:person.01151436636.46 schema:affiliation https://www.grid.ac/institutes/grid.5645.2
177 schema:familyName Van der Gaast
178 schema:givenName A
179 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01151436636.46
180 rdf:type schema:Person
181 sg:person.01276413771.32 schema:affiliation https://www.grid.ac/institutes/grid.417924.d
182 schema:familyName Hospitel
183 schema:givenName M
184 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01276413771.32
185 rdf:type schema:Person
186 sg:person.01313363470.43 schema:affiliation https://www.grid.ac/institutes/grid.417924.d
187 schema:familyName Oprea
188 schema:givenName C
189 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01313363470.43
190 rdf:type schema:Person
191 sg:person.01322677514.61 schema:affiliation https://www.grid.ac/institutes/grid.5645.2
192 schema:familyName Van Doorn
193 schema:givenName L
194 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01322677514.61
195 rdf:type schema:Person
196 sg:person.0676412775.30 schema:affiliation https://www.grid.ac/institutes/grid.418596.7
197 schema:familyName Tresca
198 schema:givenName P
199 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0676412775.30
200 rdf:type schema:Person
201 sg:person.0712330270.51 schema:affiliation https://www.grid.ac/institutes/grid.418596.7
202 schema:familyName Tosi
203 schema:givenName D
204 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0712330270.51
205 rdf:type schema:Person
206 sg:person.07565335014.02 schema:affiliation https://www.grid.ac/institutes/grid.5645.2
207 schema:familyName Eskens
208 schema:givenName F A L M
209 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07565335014.02
210 rdf:type schema:Person
211 sg:pub.10.1007/bf02353487 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008091929
212 https://doi.org/10.1007/bf02353487
213 rdf:type schema:CreativeWork
214 sg:pub.10.1007/s00280-002-0529-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006440096
215 https://doi.org/10.1007/s00280-002-0529-0
216 rdf:type schema:CreativeWork
217 sg:pub.10.1007/s002800050611 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000213160
218 https://doi.org/10.1007/s002800050611
219 rdf:type schema:CreativeWork
220 sg:pub.10.1038/nrc1628 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017276673
221 https://doi.org/10.1038/nrc1628
222 rdf:type schema:CreativeWork
223 sg:pub.10.1038/sj.bjc.6600645 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000892697
224 https://doi.org/10.1038/sj.bjc.6600645
225 rdf:type schema:CreativeWork
226 sg:pub.10.1038/sj.bjc.6601261 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019402280
227 https://doi.org/10.1038/sj.bjc.6601261
228 rdf:type schema:CreativeWork
229 https://app.dimensions.ai/details/publication/pub.1082649028 schema:CreativeWork
230 https://doi.org/10.1002/cncr.24975 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026739049
231 rdf:type schema:CreativeWork
232 https://doi.org/10.1016/s0959-8049(99)00122-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1039441230
233 rdf:type schema:CreativeWork
234 https://doi.org/10.1016/s0959-8049(99)00174-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000814734
235 rdf:type schema:CreativeWork
236 https://doi.org/10.1093/annonc/mdr413 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018078452
237 rdf:type schema:CreativeWork
238 https://doi.org/10.1093/jnci/92.3.205 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032301848
239 rdf:type schema:CreativeWork
240 https://doi.org/10.1158/0008-5472.can-06-4018 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003856751
241 rdf:type schema:CreativeWork
242 https://doi.org/10.1158/1078-0432.ccr-11-3376 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012763105
243 rdf:type schema:CreativeWork
244 https://doi.org/10.1158/1078-0432.ccr-13-0427 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003465176
245 rdf:type schema:CreativeWork
246 https://doi.org/10.1182/blood.v99.6.2060 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008985812
247 rdf:type schema:CreativeWork
248 https://doi.org/10.1200/jco.1998.16.1.187 schema:sameAs https://app.dimensions.ai/details/publication/pub.1083201635
249 rdf:type schema:CreativeWork
250 https://doi.org/10.1200/jco.1999.17.5.1413 schema:sameAs https://app.dimensions.ai/details/publication/pub.1074460860
251 rdf:type schema:CreativeWork
252 https://doi.org/10.1200/jco.1999.17.8.2341 schema:sameAs https://app.dimensions.ai/details/publication/pub.1074549851
253 rdf:type schema:CreativeWork
254 https://doi.org/10.1200/jco.2005.02.027 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017384575
255 rdf:type schema:CreativeWork
256 https://doi.org/10.1200/jco.2005.05.0294 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026468715
257 rdf:type schema:CreativeWork
258 https://www.grid.ac/institutes/grid.417924.d schema:alternateName Sanofi (France)
259 schema:name Division of Biostatistics & Programming, Sanofi, 13 Quai Jules Guesde, 94400 Vitry-Sur-Seine, France.
260 Division of Drug Disposition DSAR, Sanofi, 1 Avenue Pierre Brossolette, 91380 Chilly-Mazarin, France.
261 Oncology Division and Trial Operations Department, Sanofi, 13 Quai Jules Guesde, 94400 Vitry-Sur-Seine, France.
262 rdf:type schema:Organization
263 https://www.grid.ac/institutes/grid.418596.7 schema:alternateName Institute Curie
264 schema:name Clinical Research Unit, Institut Curie, 26, rue d'Ulm, 75231 Paris Cedex 05, France.
265 rdf:type schema:Organization
266 https://www.grid.ac/institutes/grid.5645.2 schema:alternateName Erasmus University Medical Center
267 schema:name Department of Medical Oncology, Erasmus MC Cancer Institute, PO Box 2040, 3000 CA Rotterdam, The Netherlands.
268 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...